Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-154

First 154 Last

Share
Profile

Follow
Odds&Evens

2,582 Posts.

762

26/06/24

09:14

Post #: 74489697
Share

Originally posted by Taureanbull: ↑

The biggest selling drug , Keytruda, has 31 different FDA approvals. That’s why it so valuable!

If one takes the time to read the company presentation, it’s clear IMU is using the same strategy to create value.

The presentation highlights EXPANSION trials for AZER-Cel , Vaxinia, Oncarlytics.

When BP comes to run the ruler over IMU they will find mountains of data. In many different cancers. Following the path beaten by Merck.

That’s 3 platforms which are all interconnected. Azer-cel being our very own CD19 CarT therapy can be used standalone or in combo with Oncarlytics.

Marck is valued at $360bn with 50% of sales from one drug Keytruda , which only has 4 years left of patent protection.

What LC and IMU are creating here is absolutely unique. Both the Azer-Cel and VAXINIA platform are already proven . And ticked off by the FDA, for progression towards approvals .

So far ONCARLYTICS has proven to be safe and well tolerated. All we need now is proof of efficacy as a mono or combo therapy.

It really is hard to understand why so many people are dissatisfied with the progress.
Sounds like they need somebody to hold their hand so they don’t wet the bed!

Expand

Finally a sensible and informed post amongst a morass of unnecessary worry and conjecture. This simply takes time. Thankyou!!!

IMU Price at posting: 5.7¢ Sentiment: Buy Disclosure: Held
36 Upvote

1 Great analysis

Reply

Top Stories

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

GRE

Greentech finds lithium trend across 5.5 km at WA's Kobe South

AW1

American West does it again at Storm with visually identified thick copper hits at Cyclone, Lightning Ridge

LGM

Legacy shares jump on discovery of multiple epithermal veins at Bauloora JV

PYC

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

There are more pages in this discussion • 57 more messages in this thread...

First 154 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.4¢		Change 0.003(5.88%)		Mkt cap ! $396.8M

Open	High	Low	Value	Volume
5.1¢	5.7¢	5.1¢	$1.713M	31.55M

Buyers (Bids)

No.	Vol.	Price($)
9	623619	5.4¢

Sellers (Offers)

Price($)	Vol.	No.
5.5¢	50000	1

View Market Depth

No.	Vol.	Price($)
9	623619	0.054
12	2041256	0.053
10	2155178	0.052
12	966719	0.051
36	3334835	0.050

Price($)	Vol.	No.
0.055	50000	1
0.056	711256	6
0.057	1552780	8
0.058	1392228	10
0.059	1415548	10

Last trade - 16.10pm 10/07/2024 (20 minute delay)

IMU (ASX) Chart

Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-154

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Greentech finds lithium trend across 5.5 km at WA's Kobe South

American West does it again at Storm with visually identified thick copper hits at Cyclone, Lightning Ridge

Legacy shares jump on discovery of multiple epithermal veins at Bauloora JV

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-154

Top Stories

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Greentech finds lithium trend across 5.5 km at WA's Kobe South

American West does it again at Storm with visually identified thick copper hits at Cyclone, Lightning Ridge

Legacy shares jump on discovery of multiple epithermal veins at Bauloora JV

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News